Niox trading in line with expectations

Asthma-focussed medical device company Niox said in an update on Wednesday that it continued to perform strongly in the year to date, meeting management expectations.

The AIM-traded firm, which was holding its annual general meeting, noted that it settled returns claims totaling £0.4m in January, related to its discontinued business operations.

As of 30 April, the unaudited cash balance for Niox was £23.7m, up from £19.9m at the end of December 2023, with the company maintaining a debt-free status.

Niox said it would provide a trading update for the six months ending 30 June in mid-July.

At 1240 BST, shares in Niox Group were up 1.1% at 73.4p.

Reporting by Josh White for Sharecast.com.